RESEARCH ARTICLE

HIV self-testing in Spain: A valuable testing option for men-who-have-sex-with-men who have never tested for HIV

Konstantinos Koutentakis¹, Juan Hoyos²,³*, Maria-Elena Rosales-Statkus¹,², Juan-Miguel Guerras¹, Jose Pulido³,⁴, Luis de la Fuente¹,², María-José Belza²,⁵

¹ Carlos III Health Institute, National Center of Epidemiology, Madrid, Spain, ² Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain, ³ Department of Public and Mother-child health, Faculty of Medicine, Madrid Complutense University, Madrid, Spain, ⁴ Carlos III Health Institute, National School of Health, Department of Health Programs, Madrid, Spain, ⁵ Carlos III Health Institute, National School of Health, Department of Epidemiology and Biostatistics, Madrid, Spain

* jhoyos@externos.isciii.es

Abstract

Background

We assessed the capacity of HIV self-testing to promote testing among untested men who have sex with men (MSM) and determined the most benefited subpopulations.

Methods

An online questionnaire was disseminated on several gay websites in Spain from September 2012 to April 2013. We used Poisson regression to estimate factors associated with the intention to use self-testing if already available. Among those who reported intention of use, we assessed several aspects related to the testing and linkage to care process by type of barrier reported: low perceived risk (LR), structural barriers (SB) and fear of testing positive (FTP).

Results

Of 2589 never-tested MSM, 83% would have used self-testing if already available. Intention of use was associated with age ≥30 (adj.PR, 95%CI: 1.05, 1.01–1.10), having had protected (adj.PR, 95%CI: 1.15, 1.02–1.30) or unprotected (adj.PR, 95%CI: 1.21, 1.07–1.37) anal intercourse and reporting FTP (adj.PR, 95%CI: 1.12, 1.05–1.20) or SB to access HIV testing (adj.PR, 95%CI: 1.23, 1.19–1.28). Among those who reported intention of using a self-test, 78.3% declared it their preferred option (83.8% in the SB group; p < 0.001), and 56.8% would always use this testing option (60.9% among the SB group; p = 0.001). In the case of obtaining a positive self-test, 69.3% would seek confirmatory testing, 15.3% would self-test again before taking any decision and 13.0% reported not being sure of what they would do.
Conclusion
HIV self-testing in Spain has the potential of becoming a highly used testing methodology for untested MSM and could represent the gateway to testing especially among older, at risk MSM who report SB or FTP as main barriers to testing.

Introduction
In Spain and in the rest of Western Europe, men who have sex with men (MSM) are the population most affected by HIV. Of the 1270 new HIV cases notified among MSM during 2016 39.4% were diagnosed at a late stage of infection (< 350 mm$^3$ CD4 count at diagnosis) [1]. From a public health perspective, to promote earlier diagnosis and to reduce the undiagnosed fraction of the epidemic is one of the main priorities in HIV prevention programs worldwide because treatment reduces infectiousness and contributes to stop onward transmission [2, 3].

Recommendations for MSM are that an HIV test should be performed at least every 12 months and every 3 when having unprotected sex with casual partners [4]. However, studies across Europe point out that these recommendations are far from being met [5–8]. In fact, the first European men who have sex with men internet survey (EMIS) found that the percentage of untested MSM in western European countries ranged from 16.2% in France to 37.2% in Finland [9].

In Spain, HIV testing is offered free of cost at all levels of the public health system. It is also performed in a network of sexual health clinics and units that not only offer it free of cost but also anonymously. Confidential and anonymous rapid testing is also conducted for free by a number of community based organisations (CBO) and, in 5 regions, there are also pharmacy based rapid testing programmes where those who wish, can get tested by a pharmacist. In spite of the variety of settings, 26.1% of MSM in Spain have never been tested for HIV [10].

Barriers to testing include reasons related to risk perception, fear of stigma and discrimination and to health consequences derived from a positive result [11]. Additionally, there are also a number of structural barriers related to the characteristics of the diagnostic settings that include lack of anonymity and or/ confidentiality, having to wait, having to return to receive the result of a test, and the need to discuss sexual behaviours [11].

In this sense, self-testing is a methodology that could help to alleviate some of the aforementioned barriers. First approved in the US in 2012, self-testing has slowly but steadily spread across high-income countries. At present it is being marketed in the United Kingdom (UK), France, Belgium and Italy. In Spain self-testing kits started to be commercialized in January 2018 [12]. Self-testing provides individuals with the opportunity of learning their serostatus conveniently since it requires no appointments, no queues, no time invested in getting to testing sites and no pre and post-test discussion. On the other hand it also raises some concerns. The lack of face to face pre-test contact with a professional is one of the most common ones. Thus, it is important to provide good written and online materials to inform potential users both about the benefits and limitations (i.e window period and the need of a confirmation test) of self-testing. Coping with a positive self-test alone is another concern and support mechanisms need to be put into place to offer support and information for those in this situation. Finally there are also concerns about users who obtain a reactive self-test and do not seek confirmation testing and subsequent linkage to specialist care [13–16].

If self-testing is capable of eliminating some of the known barriers and of facilitating access to HIV testing among those who remain untested, it is crucial to know which subpopulations...
would use it. The literature assessing the impact that the introduction of self-testing could have in untested MSM is very limited and mostly comes from Australia and the US. In Europe, we found very few studies assessing this aspect in this population [17–19] and none of them focus on never tested individuals. Furthermore, we do not know what type of barriers self-testing would help to remove and what would happen in the case of receiving a positive result. Acts following a reactive self-test and preferences regarding confirmation sites remain unknown and are important elements that need to be taken into account for the future development of the strategy.

In the present paper we assess the impact that self-testing could have among untested MSM in Spain. We identify the subgroups that would benefit the most from its introduction and assess self-testing’s capacity of overcoming barriers that deter people from testing. Additionally we also investigate several key aspects related to the testing process and linkage to care that need to be considered to assure an effective introduction of this methodology.

Methods

Study participants

Inclusion criteria were being $\geq 18$ years of age and having reported lifetime sex with other men. Of the 9489 participants who met the inclusion criteria and self-identified as HIV negative or had an unknown serostatus, we selected 2818 MSM who reported no previous HIV testing experience. Additionally, we excluded 229 who did not answer the main outcome variable (would have used self-testing if already available). Thus, 2589 participants were included in the final analysis. No incentives were given for participation.

Study procedures and measurements

We conducted an internet based survey between September 2012 and April 2013. Our study was advertised mainly in gay dating websites operating in Spain. Details about the study procedures have been reported elsewhere [20]. Briefly, those who chose to access the survey website were directed to an informative screen. Here, participants learned about the purpose of the study and the estimated time to complete the questionnaire (15 min). They were also informed about the fact that no Internet Protocols or cookies were collected and that data was collected confidentially and anonymously. The questions were designed to elicit no identifying information. Thus, participants were asked to report their age in years rather than their date of birth. Likewise, we did not include questions on the city or town of residence; instead, we asked only about the approximate number of inhabitants. Given the online nature of the study, written consent was obtained by an “I agree to participate” button which was presented to participants at the end of the informative screen. Once they clicked, they accessed the questionnaire. The study and all its materials (including the questionnaire) were approved by the Carlos III health institute ethical committee (CEI PI 70_2015). All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Study did not include minors.

The questionnaire was designed in Spanish and collected data on socio-demography, lifestyle, sexual behaviours, testing history and several aspects related to HIV self-testing. The main outcome for this analysis was intention to use self-testing which was assessed with the question “Would you have used a self-test for HIV, had it been available in pharmacies in Spain?”. Replies initially were set as “yes”, “probably yes”, “not sure”, “probably no”, “no” and were transformed into a binary variable for analysis: “yes/probably yes” and “I am not sure/probably no/no”.

To assess the barriers of access to HIV testing we used a question with eleven closed response options and one open-ended. Participants were asked to choose their single most important reason. For the analysis, they were recoded into a four-category variable, as follows:

A. Low perceived risk for HIV, which included the options: “I found myself very healthy”, “I thought that with my behaviours I could not be infected”.

B. Fears of testing positive, which included: “Fear of the consequences for my health”, “Fear of not being able to get/lose my job”, “Fear of not being able to get/lose a residence permit”, “Fear of rejection or discrimination”.

C. Structural barriers, including the options: “I didn’t want to go to my GP/health center”, “Concerns arising from the loss of anonymity while being tested”, “I knew I had to wait several days to get the results”, “I wanted to do it in a private centre but had no money”, “Feel discomfort answering intimate questions”

D. “Other reason”: To allow participants to express another reason not listed among the aforementioned.

The questions of the survey used for this analysis can be found as supporting information (S1 Appendix).

**Statistical analysis**

First, we performed a descriptive analysis of the main characteristics of never tested MSM.

Second, we calculated the proportion of participants that reported having intentions of using a self-test if already available and cross-tabulated our data by relevant sociodemographic and behavioral variables as well as by type of self-reported barrier for testing.

To address associations between intention to use self-testing and MSM characteristics, we calculated crude and adjusted prevalence ratios (PRs) and their corresponding 95% confidence intervals (CIs). We chose to use poisson regression with robust variance because it is a better alternative than logistic regression in cross-sectional studies with frequent outcomes [21, 22]. All the statistically significant factors at p < 0.2 in the single variable analysis were introduced a multivariable regression model. We used the minimum Akaike information criteria (AIC) values to perform model comparisons and select the optimal model. Respondents with missing data on > 1 variables of the multivariable model, were not included in the regression model.

We performed the analysis using STATA 11 software (StataCorp, Texas, United States, United States).

A third level of analysis, focused on those who reported intention to use a self-test. In this group, we assessed the preference towards self-testing among all testing options, the type of self-test preferred (blood/oral) and whether they would use it alone or accompanied by someone. We also assessed the number of times they would have used a self-test, in what way they would incorporate it to their usual testing pattern, and what would be their preferred setting to seek for a confirmation test if the self-test was reactive. This analysis has been stratified by the type of barrier self-reported by participants and the relationship between the categorical variables was assessed using Pearson’s Chi-square test. Statistical significance was defined as a two-tailed p value of less than 0.05.

**Results**

Some 91.8% of all participants were born in Spain, 44.8% were 30 years of age or older and 46.7% had finished a university degree. In the preceding 12 months, most had lived in Spain (96.0%) in a city of more > = 100.000 inhabitants (58.1%). Additionally, 41.3% reported
having had sex with men and women, 20.3% had kept their sex life with other men in total secrecy and 60.2% were not related to the gay scene (Table 1).

More than half (56.0%) had had at least one unprotected anal intercourse (UAI) in the last 12 months, 7.2% had ever paid for sex, 4.1% had ever been paid for sex and 25.1% reported having been diagnosed with a sexually transmitted infection (STI). Very few (1.1%) had ever injected drugs (Table 1).

Regarding the reasons for never having been tested before, 48.2% of the participants reported low perceived risk which included the following reasons: "I thought that with my behaviors I could not be infected" (37.3%) and "I found myself very healthy" (10.5%). Structural barriers were reported by 36.4% and included: "Concerns arising from the loss of anonymity" (16.5%), "Feeling discomfort answering intimate questions" (8.3%), "I didn’t want to go to my GP/health center" (7.7%), "I knew I had to wait several days to get the results" (1.9%), "I wanted to do it in a private center but had no money" (1.5%). Fears derived from testing positive were reported by 8.9% of the participants and included "Fear of the consequences for my health" (6.1%), "Fear of rejection or discrimination" (2.1%), "Fear of not being able to get/lose work" (0.5%) and "Fear of not being able to get/lose residence permit" (0.1%). The remaining 6.4% of the participants reported "other reasons".

The overall proportion of participants who reported intentions of using a self-test if already available, was of 83.5% (95%CI: 82.0–84.9): 53.3% answered “yes” and 30.2% “probably yes”.

The results of the poisson regression analysis to assess the association of lifestyle and behavioral characteristics with the intention to use self-testing are shown in Table 1. In the multivariate model, variables that remained significantly associated with intention to use self-testing were age of \( \geq 30 \) years (PR, 95%CI: 1.05, 1.01–1.10), having had anal intercourse in the last twelve months either protected or not (PR, 95%CI: 1.15, 1.02–1.30; PR, 95%CI: 1.21, 1.07–1.37; respectively), reporting fears derived of testing positive (PR, 95%CI: 1.23, 1.19–1.28) and structural barriers to get tested for HIV (PR, 95%CI: 1.23, 1.19–1.28 (Table 1). The proportion of missing data of the independent variables are included as supplementary material (S1 Table).

The proportion of participants that identified self-testing as their preferred testing option was of 78.3% and was higher among those who reported structural barriers (83.8%) than among those who were never testers because of low risk perception (74.5%) or fear related reasons (71.0%) (p<0.001). Almost half (45.9%) reported that they would be willing to use any of the two self-testing options (blood or saliva) and 84.5% that they would prefer to use it alone instead of with someone (Table 2).

Participants who reported fear and structural related barriers tended to think they would have used it more times (p<0.001) than those who reported low risk perception or fear. If approved, self-testing would always be used by 56.8% of the participants and those who reported structural barriers chose this option more frequently (60.9%) than the other two groups (p = 0.013) (Table 2).

In the case of receiving a positive result, the preferred confirmation sites would be primary care (30.0%) and sexual health clinics (29.7%), although a substantial percentage of MSM with fear related barriers (25.2%) reported not being sure of what would they do (p<0.001) (Table 2).

**Discussion**

A large majority of the untested MSM we recruited online reported that they would have used an HIV self-test if already available. Intention to use was especially high among older MSM who reported anal intercourse in the last 12 months and among those who reported barriers to
|                                | Total (N = 2589) | Participants with intentions to use self-testing (N = 2161) | cPR  | 95% CIs | P  | aPR  | 95% CIs |
|--------------------------------|-----------------|----------------------------------------------------------|------|---------|----|------|---------|
| **Age**                        |                 |                                                          |      |         |    |      |         |
| <30 years old                  | 1428            | 1160                                                     | 1.00 | 1.00    |    | 1.00 | 1.00    |
| ≥30 years old                  | 1158            | 998                                                      | 1.06 | 1.03–1.10| 0.001| 1.05 | 1.01–1.10|
| **Education level**            |                 |                                                          |      |         |    |      |         |
| <University                    | 1376            | 1159                                                     | 0.98 | 0.95–1.02| 0.288|      |         |
| ≥University                    | 1206            | 997                                                      | 0.95 | 0.91–0.99 | 0.010| 0.98 | 0.94–1.02|
| **Place of residence**         |                 |                                                          |      |         |    |      |         |
| Latin-America                  | 23              | 21                                                       | 1.00 |         |    |      |         |
| Other European country         | 64              | 50                                                       | 0.86 | 0.71–1.03 | 0.091| 0.86 | 0.70–1.05|
| Spain                          | 2310            | 1938                                                     | 0.92 | 0.81–1.04 | 0.193| 0.93 | 0.79–1.08|
| Other Country                  | 10              | 9                                                        | 1.04 | 0.99–1.09 | 0.145| 1.01 | 0.97–1.06|
| **Settlement size (inhabitants)** |               |                                                          |      |         |    |      |         |
| >100,000                       | 1389            | 1156                                                     | 1.00 |         |    |      |         |
| <100,000, (within 30 km of a big city) | 619       | 518                                                      | 1.00 | 0.96–1.05 | 0.798| 1.01 | 0.97–1.05|
| <100,000, (> = 30 km of a big city) | 383           | 330                                                      | 1.00 | 0.99–1.09 | 0.145| 1.01 | 0.97–1.06|
| **Cohabitation**               |                 |                                                          |      |         |    |      |         |
| Lives alone                    | 830             | 712                                                      | 1.00 |         |    |      |         |
| Lives with sexual partner      | 484             | 418                                                      | 1.00 | 0.96–1.05 | 0.769| 0.99 | 0.95–1.04|
| Lives with others (not a sexual partner) | 1081  | 880                                                      | 0.95 | 0.91–0.99 | 0.010| 0.98 | 0.94–1.02|
| **Sexual partners (lifetime)** |                 |                                                          |      |         |    |      |         |
| Men & women                    | 1070            | 898                                                      | 1.00 |         |    |      |         |
| Men only                       | 1519            | 1263                                                     | 1.00 |         |    |      |         |
| **Disclosure of sexual orientation** |               |                                                          |      |         |    |      |         |
| Has not disclosed his sexual orientation | 492  | 403                                                      | 1.00 |         |    |      |         |
| Has disclosed his sexual orientation to someone | 1937 | 1639                                                     | 1.00 |         |    |      |         |
| **Relation with gay culture**  |                 |                                                          |      |         |    |      |         |
| Member of a gay CBOc           | 59              | 42                                                       | 1.00 |         |    |      |         |
| Not member of gay CBO but frequents the gay scene | 875  | 755                                                      | 1.21 | 1.03–1.43 | 0.022| 1.08 | 0.93–1.27|
| Not related to gay scene       | 1410            | 1176                                                     | 1.17 | 0.99–1.38 | 0.058| 1.06 | 0.90–1.23|
| **Anal intercourse & condom use** |               |                                                          |      |         |    |      |         |
| No anal intercourse            | 129             | 86                                                       | 1.00 |         |    |      |         |
| Had, but all were protectedd  | 937             | 759                                                      | 1.22 | 1.07–1.38 | 0.002| 1.15 | 1.02–1.30|
| Had unprotected anal intercourse | 1357        | 1190                                                     | 1.32 | 1.16–1.49 | 0.001| 1.21 | 1.07–1.37|
| **Has been paid for sex**      |                 |                                                          |      |         |    |      |         |
| Yes                            | 99              | 84                                                       | 1.00 |         |    |      |         |
| No                             | 2340            | 1963                                                     | 0.99 | 0.91–1.08 | 0.793|      |         |
| **Has paid for sex**           |                 |                                                          |      |         |    |      |         |
| Yes                            | 176             | 150                                                      | 1.00 |         |    |      |         |
| No                             | 2266            | 1900                                                     | 0.98 | 0.92–1.05 | 0.618|      |         |
| **Injection drug use**         |                 |                                                          |      |         |    |      |         |
| Never                          | 2384            | 2002                                                     | 1.00 |         |    |      |         |
| Yes, > = 12 months ago        | 15              | 11                                                       | 0.87 | 0.64–1.19 | 0.385|      |         |
| Yes, in the last 12 months     | 12              | 10                                                       | 0.99 | 0.77–1.28 | 0.953|      |         |
| **History of STIs**            |                 |                                                          |      |         |    |      |         |
| No                             | 1798            | 1491                                                     | 1.00 |         |    |      |         |

(Continued)
### Table 1. (Continued)

| Total (N = 2589) | Participants with intentions to use self-testing (N = 2161) |  |  |  |  |  |  |  |
|------------------|------------------------------------------------------------|---|---|---|---|---|---|---|
|                  | N   | % (col) | n   | % (row) | cPR | 95% CIs | P   | aPR | 95% CIs |
| Lifetime diagnosis of STI | 603 | 25.1 | 523 | 86.7 | 1.05 | 1.01–1.09 | 0.018 | 0.99 | 0.96–1.03 |
| **Main reason for not HIV testing** |  |  |  |  |  |  |  |  |  |
| Low perceived risk for HIV | 1236 | 48.2 | 936 | 75.7 | 1.00 |  |  |  |  |
| Fear of testing positive | 229 | 8.9 | 193 | 84.3 | 1.11 | 1.04–1.19 | 0.001 | 1.12 | 1.05–1.20 |
| Structural barriers | 931 | 36.3 | 884 | 94.9 | 1.25 | 1.21–1.30 | 0.000 | 1.23 | 1.19–1.28 |
| Other | 166 | 6.5 | 122 | 73.5 | 0.97 | 0.88–1.07 | 0.544 | 0.98 | 0.89–1.08 |

cPR: crude prevalence ratio; aPR: adjusted prevalence ratio; CI: confidence interval

* Due to missing data the numbers might not add up to totals

1 In the last 12 months

2 Community-Based Organization

3 Protection referred to condom use only

https://doi.org/10.1371/journal.pone.0210637.t001

### Table 2. Type of self-test preferred, aspects of the HIV self-testing process and potential use by type of barrier reported by those who expressed intention to use self-testing if already available.

| Type of barrier | Low risk perception | Fear | Structural barriers | Total | P |
|-----------------|----------------------|------|---------------------|-------|---|
| N, % (row)      | 936 46.5 | 193 9.6 | 884 43.9 | 2013 100.0 |      |
| Refers self-testing as the preferred testing option | 697 74.5 | 137 71.0 | 741 83.8 | 1575 78.3 | <0.001 |
| **Type of self-test preferred** |  |  |  |  | 0.60 |
| Blood | 128 13.9 | 30 15.9 | 129 14.8 | 287 14.5 |  |
| Saliva | 383 41.5 | 71 37.6 | 331 38.0 | 785 39.6 |  |
| Either | 412 44.6 | 88 46.6 | 411 47.2 | 911 45.9 |  |
| How would you prefer to use a self-test kit? |  |  |  |  | 0.64 |
| Alone | 785 84.7 | 157 82.2 | 742 84.9 | 1684 84.5 |  |
| Acompanied by someone | 142 15.3 | 34 17.8 | 132 15.1 | 308 15.5 |  |
| Times a self-test would have been used if already available |  |  |  |  | <0.001 |
| Only once | 482 51.8 | 56 29.0 | 317 36.2 | 855 42.8 |  |
| Two to thrее times | 357 38.3 | 100 51.8 | 403 46.0 | 860 43.0 |  |
| Four or more times | 92 9.9 | 37 19.2 | 156 17.8 | 285 14.2 |  |
| Frequency of use if self-test kits were available |  |  |  |  | 0.013 |
| I would never/rarely use it, I rather get tested by a trained professional | 129 14.3 | 30 16.1 | 93 10.9 | 252 13.0 |  |
| It would be my usual testing method, although I would also seek testing by trained professionals | 293 32.4 | 54 29.0 | 240 28.2 | 587 30.2 |  |
| I would always use it | 482 53.3 | 102 54.8 | 519 60.9 | 1103 56.8 |  |
| Reaction following a positive self-test |  |  |  |  | <0.001 |
| Not sure what would I do | 89 9.6 | 49 25.5 | 122 14.0 | 260 13.0 |  |

https://doi.org/10.1371/journal.pone.0210637.t002
testing not related to risk perception. Among those who expressed willingness to self-test, a large majority identified it as their preferred mode of testing and reported that, if available, they would use this method exclusively. Most would attend primary care and sexual health clinics for confirmatory purposes although a quarter of those expressing fear of the consequences of a positive result are not sure of what would they do if they obtained a positive result.

The percentage of untested MSM was slightly higher than that reported by a Spanish study that also analyzed MSM recruited online (26%) [10]. We found three European studies that assessed the willingness of MSM to use HIV self-testing kits [17–19] and proportions ranged from 54.6% [19] to figures of nearly 90% and, therefore, very similar to our results [17, 18]. Of these studies, only two assessed the association between testing history and willingness to use a self-test kit [18, 19] and they present conflicting results. Whereas in the study by Greacen et al. having never tested before was associated with interest in accessing an HIV test, in the study by Rosales et al. it was the opposite and those with previous testing experience were the ones that reported higher levels of interest in purchasing a self-test. Nevertheless, both of them include testing history as an independent variable making it impossible to assess which particular sub-groups of never testers would benefit from its approval. As far as we know, the present paper represents the first study at a European level that tries to distinguish which groups of never-testers would use it if approved.

In this sense, the fact that older age is associated with willingness to use a self-test is an important issue as they are more affected by late diagnosis in Spain [1] and elsewhere in Europe [23]. It also means that it would benefit never tested MSM with longer periods at risk of HIV acquisition and, hence, a subgroup with higher number of unknown infections as suggested in several studies [24, 25]. The fact that participants involved in UAI in the last 12 months were the ones who reported higher willingness of using a self-test kit stresses the potential of self-testing as a tool that could play an important role on promoting testing among a hard to reach population who is not using pre-existing testing options in spite of being at risk of acquiring HIV.

A key factor that has not been assessed until now is what type of barriers HIV self-testing would help to remove. Populations with different barriers will be in the need of different testing strategies. In this sense, according to our results, the group less benefited by the approval of HIV self-testing kits would be those MSM that reported low risk perception. Low risk perception affects the intention of actively seeking an HIV test and those reporting it could probably be better targeted by provider initiated strategies [26] and tailored interventions to increase their risk perception.

Self-testing kits might be better fit for those who are not willing to access existing services due to structural barriers or because of fears derived from a potential positive result. This is in line with our results. Those facing structural barriers are a relevant group in size in our sample and represent almost 4 in 10 of the untested MSM. In Spain, where testing services are provided in a large variety of contexts, structural barriers could have to do more with the acceptability rather than with the availability of services. In this sense, some characteristics of self-testing such as complete anonymity, not having to deal with the anxiety of long periods of wait for the test results, convenience, or not having to discuss one’s sex life with a health provider, might be some of the reasons that make this testing option such a valued option for untested MSM who reported structural barriers. Never tested participants affected by barriers related to fears derived from a positive result are a much smaller group in size but would also benefit greatly from the introduction of self-testing kits.

According to our results, self-testing could become a very popular option among untested MSM. Most participants reported that it would become their favorite testing option and more than half said that they would only use this option. This however represents a major challenge:
providing HIV confirmation testing and linkage to care services for all those who obtain a positive self-test. In this sense, further studies should be carried out to monitor confirmation testing and linkage to care among individuals receiving a positive self-test as data on the subject are extremely scarce at the moment [27, 28]. Most of our participants reported that they would seek for confirmation in the case of obtaining a positive self-test but, especially among those who faced fear related barriers, there is a substantial group that reported not being sure of what they would do in this scenario. It is important to ensure that in the case of obtaining a positive result a confirmatory test is performed within a time period that allows fulfilling the requirements of optimal linkage to care.

Several limitations need to be considered when interpreting these results. Although it is true that online dating websites are an increasingly frequent way of socializing and meeting new sex partners, the generalisation of these results to the overall untested MSM population needs to be made with caution. The data analysed in this paper, was collected immediately after the approval of self-testing in the US. Since then, self-testing has also been approved and legalised in several other European countries. MSM could have become more knowledgeable about it and some current opinions could be different to those from back in 2012–2013. Additionally, we do not know how answers based on the hypothetical situation of self-testing already being marketed, can translate into actual use. Those who expressed intentions of using it, could be reflecting a preference or sympathy towards this option. This however, does not mean it would necessarily lead to the purchase and use of a self-test kit when made available.

The proportion of missing values among those who reported medium or low testing intentions tended to be slightly higher than among those with high testing intentions (S1 Table). This needs to be taken into account when interpreting the results as it could be leading to an overestimation of those reporting high testing intentions. Nevertheless, its influence should be minimal given that the proportion of missing data is always under the 10% mark (0.1%- 9.5%). The difference of missing value rates should not change the interpretation of the results of our main outcome variable which is very frequent (83.5%).

The high acceptability of this testing method underlines its capacity of being a potentially relevant tool to promote testing among a severely undertested population. It would especially benefit subpopulations of older age, that have been involved in unprotected anal sex and that do not want to access already existing services due to structural barriers or because of fear derived from a positive result. Its high potential impact also represents a major challenge to ensure clear confirmation pathways to enable swift and effective linkage to care for those who obtain a positive self-test result.

Supporting information

S1 Appendix. Survey questions used in this study.

S1 Table. Percentage of missing values in variables included in the final multivariable model by testing intention (N = 2589) * fisher’s exact test.

S1 Dataset. Data used in the analysis.

Author Contributions

Conceptualization: María-Elena Rosales-Statkus, Luis de la Fuente, María-José Belza.
Data curation: Konstantinos Koutentakis, María-Elena Rosales-Statkus.

Formal analysis: Konstantinos Koutentakis, Juan Hoyos, María-Elena Rosales-Statkus, Luis de la Fuente.

Funding acquisition: Luis de la Fuente, María-José Belza.

Investigation: Juan-Miguel Guerras, Luis de la Fuente, María-José Belza.

Methodology: Luis de la Fuente, María-José Belza.

Project administration: Luis de la Fuente, María-José Belza.

Resources: María-José Belza.

Supervision: Juan Hoyos, María-Elena Rosales-Statkus, Luis de la Fuente, María-José Belza.

Validation: Juan-Miguel Guerras, María-José Belza.

Visualization: Juan-Miguel Guerras.

Writing – original draft: Konstantinos Koutentakis, Juan Hoyos, Jose Pulido, Luis de la Fuente, María-José Belza.

Writing – review & editing: Jose Pulido, Luis de la Fuente, María-José Belza.

References

1. Centro Nacional de Epidemiología. Vigilancia Epidemiológica del VIH/SIDA en España. Sistema de información sobre Nuevos Diagnósticos de VIH y Registro Nacional de SIDA. Actualización 30 junio de 2017. Available at: http://www.msssi.gob.es/ciudadanos/enfermedades/entTransmisibles/sida/vigilancia/InformeVIH_SIDA_2017_NOV2017.pdf. Accessed 3/12/2018.

2. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005; 39(4):446–53. PMID: 16010168

3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011; 365(6):493–505. https://doi.org/10.1056/NEJMoa1105243 PMID: 21767103

4. European Centre for Disease Prevention and Control. HIV and STI prevention among men who have sex with men. Available at: http://ecdc.europa.eu/en/publications/Publications/hiv-sti-prevention-among-men-who-have-sex-with-men-guidance.PDF. Accessed 3/12/2018.

5. Prati G, Breveglieri M, Lelleri R, Furegato M, Gios L, Pietrantoni L. Psychosocial correlates of HIV testing among men who have sex with men in Italy: a cross-sectional study. Int J STD AIDS. 2013; 25(7):496–503. https://doi.org/10.1177/0956462413515193 PMID: 24352132

6. Witzel TC, Melendez-Torres GJ, Hickson F, Weatherburn P. HIV testing history and preferences for future tests among gay men, bisexual men and other MSM in England: results from a cross-sectional study. BMJ Open. 2016; 6(9):e011372. https://doi.org/10.1136/bmjopen-2016-011372 PMID: 27630068

7. den DC, Doppen M, Schmidt AJ, Op de CE. Determinants of never having tested for HIV among MSM in the Netherlands. BMJ Open. 2016; 6(1):e009480. https://doi.org/10.1136/bmjopen-2015-009480 PMID: 26758261

8. Carvalho C, Fuertes R, Lucas R, Martins A, Campos MJ, Mendao L, et al. HIV testing among Portuguese men who have sex with men—results from the European MSM Internet Survey (EMIS). HIV Med. 2013; 14 Suppl 3:15–8.

9. The EMIS Network. EMIS 2010: The European Men Who Have Sex With Men Internet Survey. Findings from 38 countries. Available at: https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/EMIS-2010-european-men-who-have-sex-with-men-survey.pdf. Accessed 7/05/2018

10. Fernandez-Davila P, Folch C, Ferrer L, Soriano R, Diez M, Casabona J. Who are the men who have sex with men in Spain that have never been tested for HIV? HIV Med. 2013; 14 Suppl 3:44–8.

11. European Centre for Disease Prevention and Control. HIV testing: increasing uptake and effectiveness in the European Union. Available at: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/101129_GUI_HIV_testing.pdf. Accessed 3/12/2018
12. Real Decreto 1083/2017, de 29 de diciembre, por el que se modifica el Real Decreto 1662/2000, de 29 de septiembre, sobre productos sanitarios para diagnóstico «in vitro», con objeto de regular la venta al público y la publicidad de los productos de autodiagnóstico para la detección del VIH. Boletín oficial del estado. pp 130888–130889, (2018).

13. Frith L. HIV self-testing: a time to revise current policy. Lancet. 2007; 369(9557):243–5. https://doi.org/10.1016/S0140-6736(07)60113-5 PMID: 17240291

14. Spielberg F, Levine RO, Weaver M. Self-testing for HIV: a new option for HIV prevention? Lancet Infect Dis. 2004; 4(10):640–6. https://doi.org/10.1016/S1473-3099(04)0150-8 PMID: 15451493

15. Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? Ann Intern Med. 2006; 145(6):459–62. PMID: 16983134

16. Wright AA, Katz IT. Home testing for HIV. N Engl J Med. 2006; 354(5):437–40. https://doi.org/10.1056/NEJMp058302 PMID: 16452553

17. Flowers P, Riddell J, Park C, Ahmed B, Young I, Frankis J, et al. Preparedness for use of the rapid result HIV self-test by gay men and other men who have sex with men (MSM): a mixed methods exploratory study among MSM and those involved in HIV prevention and care. HIV Med. 2017; 18(4):245–55. https://doi.org/10.1111/hiv.12420 PMID: 27492141

18. Greacen T, Friboulet D, Blachier A, Fugon L, Hefez S, Lorente N, et al. Internet-using men who have sex with men would be interested in accessing authorised HIV self-tests available for purchase online. AIDS Care. 2013; 25(1):49–54. https://doi.org/10.1080/09540121.2012.687823 PMID: 22670681

19. Rosales-Statkus ME, de la Fuente L, Fernandez-Balbuena S, Figueroa C, Fernandez-Lopez L, Hoyos J, et al. Approval and Potential Use of Over-the-Counter HIV Self-Tests: The Opinion of Participants in a Street Based HIV Rapid Testing Program in Spain. AIDS Behav. 2015; 19(3):742–84. https://doi.org/10.1007/s10461-014-0975-9 PMID: 25537965

20. Koutentakis K, Rosales-Statkus ME, Hoyos J, Fernandez-Balbuena S, Ruiz M, Agusti C, et al. Knowledge and use of unauthorized HIV self-test kits among men who have sex with men in Spain, following approval of an over-the-counter self-test in the U.S: a cross-sectional study. BMC Public Health. 2016; 16:532. https://doi.org/10.1186/s12889-016-3204-9 PMID: 27390840

21. Barroso AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC medical research methodology. 2003; 3:21. https://doi.org/10.1186/1471-2288-3-21 PMID: 14567763

22. Lee J, Tan CS, Chia KS. A practical guide for multivariate analysis of dichotomous outcomes. Annals of the Academy of Medicine, Singapore. 2009; 38(8):714–9. PMID: 19736577

23. European Centre for Disease Prevention and Control. HIV/AIDS surveillance in Europe 2017–2016 data. Available at: https://ecdc.europa.eu/sites/portal/files/documents/20171127-Annual_HIV_Report_Cover%2BInner.pdf. Cited 3/13/2018.

24. Nash SG, Furegato M, Gill NO, Connor NAC. HIV testing in England: 2017 report London2017. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/666478/HIV_testing_in_England_2017_report.pdf.

25. Diez M, Bleda MJ, Varela JR, Oronana J, Azpiri MA, Vall M, et al. Trends in HIV testing, prevalence among first-time testers, and incidence in most-at-risk populations in Spain: the EPI-VIH Study, 2000 to 2009. Euro Surveill. 2014; 19(47):20971. PMID: 25443036

26. WHO/UNAIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. Available at: http://apps.who.int/iris/bitstream/handle/10665/43688/9789241595568_eng.pdf?sequence=1. Cited 3/13/2018

27. Katz D, Golden M, Hughes J, Farquhar C, Steckler J. Acceptability and ease of use of home-self-testing for HIV among MSM. In: Conference on retroviruses and opportunistic infections (CROI 2012); 3/5/2012, 2012.

28. Mayer K, Tomassili J, Gelman M, Altfield M, Allen T. HIV self-testing among men who have sex with men (MSM): acceptability of biweekly finger pricks to perform the alere determine™ HIV-1/2 Ag/Ab assay. In: AIDS 2014-XX international AIDS conference, July 2014, Melbourne.